 - Data from the study to provide valuable insights as the Company advances XCART lead program in Non-Hodgkin lymphoma NHL towards Investigational New Drug IND filing in the United States - Study will evaluate the XCART process of neoantigen identification and generation of tumor-specific CAR T candidates, in a real-world clinical setting FRAMINGHAM, MA ACCESSWIRE March 29, 2021 Xenetic Biosciences, Inc. NASDAQ:XBIO Xenetic or the Company, a biopharmaceutical company focused on advancing XCART, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today announced it has received approval to commence its exploratory patient biopsy study in Eastern Europe evaluating XCART. The start of this study represents an important step forward in our preclinical development program, and we look forward to evaluating the XCART platform applied to tumor samples from NHL patients currently under evaluation or in treatment at the study site. 